R&D News | pharmaphorum

News

Belite plans filing for oral Stargardt drug after phase 3 wi...

The first therapy for sight-robbing Stargardt disease could be on the way, as Belite Bio's tinlarebant hits the mark in a phase 3 trial.

News

Real-world trial of Lilly's tirzepatide starts in UK

A real-world study exploring the long-term effects of Eli Lilly's weight-loss therapy tirzepatide in primary care settings has started in the UK.

News

Is FDA about to restrict vaccination even further?

Vinay Prasad, head of CBER, is reported to be planning to tighten regulations on vaccines after concluding that COVID-19 shots caused 10 child deaths.

News

Veraxa says delayed US listing is back on track

Swiss biotech Veraxa's listing on the Nasdaq, delayed by the record 43-day US government shutdown, should now complete in the first quarter of 2026.

News

Digital platform for GPs 'could transform clinical trials'

A new digital platform designed to make it easier for GPs in the NHS to participate in clinical trials has been formally launched in the UK.

News

Young woman suffering from bleeding disorder, nosebleed

Vaderis drug lends hope to patients with bleeding disease HH...

A trial of Vaderis' AKT inhibitor engasertib finds it could be the first effective treatment for rare disease hereditary haemorrhagic telangiectasia.

Belite plans filing for oral Stargardt drug after phase 3 wi...

Real-world trial of Lilly's tirzepatide starts in UK

Is FDA about to restrict vaccination even further?

Veraxa says delayed US listing is back on track

Digital platform for GPs 'could transform clinical trials'

Vaderis drug lends hope to patients with bleeding disease HH...

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks